Financial Conflict of Interest in Clinical Psychiatry Studies: A Review

Ulas H., Binbay I. T., ALPTEKİN K.

TURK PSIKIYATRI DERGISI, cilt.19, sa.4, ss.418-426, 2008 (SSCI) identifier identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 19 Sayı: 4
  • Basım Tarihi: 2008
  • Dergi Adı: TURK PSIKIYATRI DERGISI
  • Derginin Tarandığı İndeksler: Social Sciences Citation Index (SSCI), Scopus, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.418-426
  • Anahtar Kelimeler: Conflict of interest, drug industry, psychiatry, psychopharmacology, bias, ANTIPSYCHOTIC-DRUGS, CHRONIC-SCHIZOPHRENIA, GHOST AUTHORSHIP, INDUSTRY, RISPERIDONE, 2ND-GENERATION, TRIALS, SPONSORSHIP, PREVALENCE, OLANZAPINE
  • Dokuz Eylül Üniversitesi Adresli: Evet

Özet

Pharmaceutical industry revenues from global pharmaceutical sales have increased 7% to $602 billion in 2005. Approximately 15% of these revenues were spent on clinical research and drug development studies. Because of the huge budget allocated to research and development studies the number of studies being conducted by pharmaceutical companies has increased. The impact of the pharmaceutical industry on clinical trials has been affected by financial conflicts of interest between researchers and the industry.